Literature DB >> 32049766

Anomalies in language as a biomarker for schizophrenia.

Janna N de Boer1,2, Sanne G Brederoo1, Alban E Voppel1, Iris E C Sommer1.   

Abstract

PURPOSE OF REVIEW: After more than a century of neuroscience research, reproducible, clinically relevant biomarkers for schizophrenia have not yet been established. This article reviews current advances in evaluating the use of language as a diagnostic or prognostic tool in schizophrenia. RECENT
FINDINGS: The development of computational linguistic tools to quantify language disturbances is rapidly gaining ground in the field of schizophrenia research. Current applications are the use of semantic space models and acoustic analyses focused on phonetic markers. These features are used in machine learning models to distinguish patients with schizophrenia from healthy controls or to predict conversion to psychosis in high-risk groups, reaching accuracy scores (generally ranging from 80 to 90%) that exceed clinical raters. Other potential applications for a language biomarker in schizophrenia are monitoring of side effects, differential diagnostics and relapse prevention.
SUMMARY: Language disturbances are a key feature of schizophrenia. Although in its early stages, the emerging field of research focused on computational linguistics suggests an important role for language analyses in the diagnosis and prognosis of schizophrenia. Spoken language as a biomarker for schizophrenia has important advantages because it can be objectively and reproducibly quantified. Furthermore, language analyses are low-cost, time efficient and noninvasive in nature.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32049766     DOI: 10.1097/YCO.0000000000000595

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  8 in total

1.  Single-nucleus RNA sequencing of midbrain blood-brain barrier cells in schizophrenia reveals subtle transcriptional changes with overall preservation of cellular proportions and phenotypes.

Authors:  Sofía Puvogel; Astrid Alsema; Laura Kracht; Cynthia Shannon Weickert; Iris E C Sommer; Bart J L Eggen; Maree J Webster
Journal:  Mol Psychiatry       Date:  2022-10-03       Impact factor: 13.437

2.  Disembodied Language in Early-Onset Schizophrenia.

Authors:  Przemysław Zakowicz; Maria Skibińska; Joanna Pawlak
Journal:  Front Psychiatry       Date:  2022-07-05       Impact factor: 5.435

Review 3.  Recent advancements in biomarker research in schizophrenia: mapping the road from bench to bedside.

Authors:  Shivangi Patel; Dilip Sharma; Ankit Uniyal; Anagha Gadepalli; Vinod Tiwari
Journal:  Metab Brain Dis       Date:  2022-03-03       Impact factor: 3.655

4.  Language in schizophrenia: relation with diagnosis, symptomatology and white matter tracts.

Authors:  J N de Boer; M van Hoogdalem; R C W Mandl; J Brummelman; A E Voppel; M J H Begemann; E van Dellen; F N K Wijnen; I E C Sommer
Journal:  NPJ Schizophr       Date:  2020-04-20

5.  Abnormal Cortical Activation Patterns Among Chinese-Speaking Schizophrenia Patients During Category and Letter Verbal Fluency Tasks Revealed by Multi-Channel Functional Near-Infrared Spectroscopy.

Authors:  Juan Li; Junlin Mu; Chenyu Shen; Guanqun Yao; Kun Feng; Xiaoqian Zhang; Pozi Liu
Journal:  Front Psychiatry       Date:  2021-11-25       Impact factor: 4.157

6.  Language production impairments in patients with a first episode of psychosis.

Authors:  Giulia Gargano; Elisabetta Caletti; Cinzia Perlini; Nunzio Turtulici; Marcella Bellani; Carolina Bonivento; Marco Garzitto; Francesca Marzia Siri; Chiara Longo; Chiara Bonetto; Doriana Cristofalo; Paolo Scocco; Enrico Semrov; Antonio Preti; Lorenza Lazzarotto; Francesco Gardellin; Antonio Lasalvia; Mirella Ruggeri; Andrea Marini; Paolo Brambilla
Journal:  PLoS One       Date:  2022-08-11       Impact factor: 3.752

Review 7.  Use of Social Media Data to Diagnose and Monitor Psychotic Disorders: Systematic Review.

Authors:  Benoit-Marie Robaglia; Alban Lejeune; Michel Walter; Sofian Berrouiguet; Christophe Lemey
Journal:  J Med Internet Res       Date:  2022-09-06       Impact factor: 7.076

8.  Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.

Authors:  Ming-Huan Zhu; Zhen-Jing Liu; Qiong-Yue Hu; Jia-Yu Yang; Ying Jin; Na Zhu; Ying Huang; Dian-Hong Shi; Min-Jia Liu; Hong-Yang Tan; Lei Zhao; Qin-Yu Lv; Zheng-Hui Yi; Feng-Chun Wu; Ze-Zhi Li
Journal:  Mil Med Res       Date:  2022-10-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.